Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines

Acta Oncologica

Volumn 43, Issue 5, 2004, Pages 443-452

  Mubashar, Muhammad ^a   Harrington, Kevin J ^b   Chaudhary, Khurram S ^c   Lalani, El Nasir ^c   Stamp, Gordon W ^c   Peters, A Michael ^a,d  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TOREMIFENE; VINBLASTINE;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN KB; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ACCUMULATION; DRUG SENSITIVITY; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HEAD AND NECK CANCER; IMMUNOCYTOCHEMISTRY; ISOTOPE LABELING; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, FLUORESCENCE; P-GLYCOPROTEIN; TECHNETIUM TC 99M SESTAMIBI; TOREMIFENE; VINBLASTINE;

EID: 3843053641     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410031048     Document Type: Article

References (40)

1. Borst P, Pinedo HM. Drug resistance. In: Peckham M, Pinedo HM, Veronesi U, eds. Oxford textbook of oncology. Oxford, UK: Oxford University Press; 1995. p. 586-601.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
3. Croop JM, Gros P, Housman DE. Genetics of multidrug resistance. J Clin Invest 1988; 81: 1303-9.
4. Goldstein LJ. MDR1 gene expression in solid tumors. Eur J Cancer 1996; 32A: 1039-50.
5. Kaye SB. Multidrug resistance: clinical relevance in solid tumors and strategies for circumvention. Curr Opin Oncol 1998; 10(Suppl 1): S15-9.
6. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumors. Eur J Cancer 1996; 32A: 1070-81.
7. Weinlander G, Kornek G, Raderer M, Hejna M, Tetzner C, Scheithauer W. Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil. J Cancer Res Clin Oncol 1997; 123: 452-5.
8. Samuels BL, Hollis DR, Rosner GL, et al. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 1997; 3: 1977-84.
9. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by antioestrogens and their major metabolites. Br J Cancer 1993; 67: 1189-95.
10. Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer 1993; 29A: 1152-7.
11. Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 1994; 54: 441-7.
12. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994; 48: 287-92.
13. Urasaki Y, Ueda T, Nakamura T. Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line. Jpn J Cancer Res 1994; 85: 659-64.
14. Desai PB, Bhardwaj R, Damle B. Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells. Cancer Chemother Pharmacol 1995; 36: 368-72.
15. Claudio JA, Emerman JT. The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells. Breast Cancer Res Treat 1996; 41: 111-22.
16. Panasci L, Jean-Claude BJ, Vasilescu D, et al. Sensitization to doxorubicin resistance in breast cancer cell lines by tamoxifen and megestrol acetate. Biochem Pharmacol 1996; 52: 1097-102.
17. Pu YS, Hsieh TS, Cheng AL, et al. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol 1996; 77: 76-85.
18. De Vincenzo R, Scambia G, Benedetti Panici P, et al. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 1996; 68: 340-8.
19. Callaghan R, Higgins CF. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 1995; 71: 294-9.
20. Stuart NS, Philip P, Harris AL, et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992; 66: 833-9.
21. Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-6.
22. Braybrooke JP, Vallis KA, Houlbrook S, et al. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 2000; 46: 27-34.
23. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-16.
24. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
25. Eagle H. Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc Soc Exp Biol Med 1955; 89: 362-4.
26. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986; 261: 7762-70.
27. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
28. Linn SC, Giaccone G, van Diest PJ, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995; 6: 679-85.
29. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
30. Verrelle P, Meissonnier F, Fonck Y, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991; 83: 111-6.
31. Wallner J, Depisch D, Hopfner M, et al. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 1991; 27: 1352-5.
32. Wang CS, LaRue H, Fortin A, Gariepy G, Tetu B. mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 1997; 45: 63-74.
33. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-84.
34. 99Tcm- sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253-7.
35. Mubashar M, Harrington KJ, Chaudhary KS, et al. Tc-99m-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer, J. Nucl Med 2002; 43: 519-26.
36. Tuquet C, Dupont J, Mesneau A, Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol Toxicol 2000; 16: 207-19.
37. Filipits M, Malayeri R, Suchomel RW, et al. Expression of the multidrug resistant protein (MRP1) in breast cancer. Anticancer Res 1999; 19: 5043-9.
38. Chen WS, Luker KE, Dahlheimer JL, Pika CM, Luker GD, Piwnica-Worms D. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of 99mTc-tetrofosmin. Biochem Pharmacol 2000; 60: 413-26.
39. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-41.
40. Burger H, Foekens JA, Look MP, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003; 9: 827-36.